A Phase 3 interventional study of rituximab [Mabthera/Rituxan] in Non-Hodgkin's Lymphoma, sponsored by Hoffmann-La Roche. Completed at 45 sites in Italy. Open to participants aged 60 Years to 75 Years. Per ClinicalTrials.gov, last updated 2017-08-15.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 178 studies testing rituximab in Lymphoma, Non-Hodgkin — 5 open to participants now, 11 under way, 2 of them phase 3. Rituximab · Lymphoma, Non-Hodgkin.
Among the 178 studies testing rituximab in Lymphoma, Non-Hodgkin, this one is the 22nd largest by enrollment of the 171 interventional ones that give a count, is one of 11 that started in 2004, is one of 29 in phase 3, and was the 115th registered.
2,288 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 283 are open to participants now.
Browse Lymphoma, Non-Hodgkin studies →5 of the 178 studies testing rituximab in Lymphoma, Non-Hodgkin are open now, in 2 countries. Recruiting first, the newest first:
Paolo Caimi, MD · Sites in United States
Ages 18+
Reid Merryman, MD · Sites in United States
Ages 18+
University of Cologne · Sites in Germany
Ages 18–99
National Cancer Institute (NCI) · Sites in United States
Ages 18–120
M.D. Anderson Cancer Center · Sites in United States
Ages 15–80
By country, each count listing its studies:
Rituximab: first FDA approval 1997 (RITUXAN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →
Of the 242 Lymphoma, Non-Hodgkin studies recruiting now, 142 (59%) set no upper age limit and 77 (32%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.
This study: 60 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
178 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 43 · Phase 2 112 · Phase 3 30 · Phase 4 5
First in 1995; this study’s year is marked. 11 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 234 is above the median of 40 across 1,883 interventional studies indexed under Lymphoma, Non-Hodgkin.
Median enrollment 38 across the 171 interventional studies. Of the 152 that completed or were terminated, 80 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
51 of 178 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 331 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
54 studies in Lymphoma, Non-Hodgkin by Hoffmann-La Roche: 1 open now, 6 under way, 1 of them phase 3. Of 47 finished, 22 (47%) have results posted.
Among the 54 studies in Lymphoma, Non-Hodgkin by Hoffmann-La Roche, this one is the 15th largest by enrollment of the 49 interventional ones that give a count, is one of 2 that started in 2004, is one of 11 in phase 3, and was the 16th registered.
Hoffmann-La Roche’s Lymphoma, Non-Hodgkin studies by the year they started, since 1997.
4 of the studies testing rituximab in Lymphoma, Non-Hodgkin that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05578976Phase 3GenmabA Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) | 2027-06 |
| NCT05583071University of CologneMethotrexate, Tafasitamab, Lenalidomide and Rituximab in Patients With PCNSL | 2027-02 |
| NCT01829958Memorial Sloan Kettering Cancer CenterComprehensive Geriatric Assessment to Predict Toxic Events in Older Patients With Non-Hodgkin Lymphoma With Imbedded Pilot Study of Pre-Phase Therapy | 2027-04 |
| NCT02727803M.D. Anderson Cancer CenterPersonalized NK Cell Therapy in CBT | 2027-05-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 178 studies testing rituximab in Lymphoma, Non-Hodgkin, from their registry updates:
Among Hoffmann-La Roche’s 54 in Lymphoma, Non-Hodgkin:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the efficacy and safety of brief induction therapy with a chemotherapeutic regimen containing MabThera, followed by either maintenance therapy with MabThera or no further therapy. The anticipated time on study treatment is 1-2 years, and the target sample size is 100-500 individuals.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: rituximab [Mabthera/Rituxan]
Drug page: Rituximab
Intravenous repeating dose
Percentage of Participants With Disease Progression or Death
PFS from randomization was measured from the date of randomization to the date of documented disease progression, relapse, or death from any cause. PFS function was estimated using Kaplan-Meier product-limit method. Responding participants and participants who were lost to follow up were censored at their last assessment date.
Time frame: 12, 24, and 34 months
PFS Randomization- Percentage of Participants Estimated to be Free of Progression at 12, 24, and 34 Months
PFS from randomization was measured from the date of randomization to the date of documented disease progression, relapse, or death from any cause. Responding participants and participants who were lost to follow-up were censored at their last assessment date. PFS was estimated using Kaplan-Meier methods.
Time frame: 12, 24, and 34 months
Percentage of Participants Estimated to be Free of Progression at 12, 24, and 36 Months
PFS from enrollment was measured from the date of enrollment to the date of disease progression, relapse, or death from any cause. Responding participants and participants who were lost to follow-up were censored at their last assessment date. Estimates of PFS function were made with the Kaplan-Meier product-limit method.
Time frame: 12, 24, and 36 months
Disease-Free Survival (DFS) From Randomization - Percentage of Participants Disease Free at 12, 24, and 36 Months
DFS was defined for all participants who achieved a complete response (CR) or unconfirmed CR (CRu) at Month 3 or later, after the completion of induction phase and was measured from the time of randomization to the date of relapse or death as a result of lymphoma or acute toxicity of treatment. Participants without relapse were censored at their last assessment date. Estimates of DFS were made using Kaplan-Meier product-limit method.
Time frame: 12, 24, and 36 months
Overall Survival (OS) From Randomization - Percentage of Participants Estimated to be Alive at 12, 24, and 34 Months
OS from randomization was defined as the date of randomization to the date of death from any cause. Participants still alive at the time of the final analysis were censored at the date of the last contact. Estimates of the OS function were made by the Kaplan-Meier product-limit method.
Time frame: 12, 24, and 34 months
Overall Survival (OS) From Randomization - Percentage of Participants With Death
OS from randomization was defined as the date of randomization to the date of death from any cause. Participants still alive at the time of the final analysis were censored at the date of the last contact. Estimates of the OS function were made by the Kaplan-Meier product-limit method.
Time frame: 12, 24, and 34 months
OS From Enrollment - Percentage of Participants Estimated to be Alive at 12, 24, and 36 Months
OS from enrollment was defined as the date of enrollment to the date of death from any cause. Participants still alive at the time of the final analysis were censored at the date of the last contact. Estimates of the OS function were made by the Kaplan-Meier product-limit method.
Time frame: 12, 24, and 36 months
Percentage of Participants With a Response During the Induction Phase
Participants without a response assessment (due to any reasons) were considered as non-responders.
Time frame: Months 1 to 8
Percentage of Participants With a Molecular Response in the Induction Phase
Molecular responders were defined as the proportion of CR/CRu participants with a positive bcl-2/IgH (non-Hodgkin's Lymphoma \[NHL\] marker) at baseline, whose laboratory values were undetectable after treatment.
Time frame: Months 5 and 8
Duration of Response Using a Traditional Approach - Percentage of Participants Estimated to Have a Sustained Response at 12, 24, and 34 Months
Duration of response (DOR) was defined for all participants who achieved a response (CR, CRu, and PR) at Month 3 or later, after the completion of induction phase and was measured from the date of randomization until the date of progression, relapse, or death as a result of follicular lymphoma (FL). Participants without relapse, progression, or death for causes other than FL were censored at their last assessment date. Analyses on this endpoint were performed with two different approaches. For the traditional approach, duration of response was estimated as the proportion of participants alive without progression or relapse of disease with the Kaplan-Meier method.
Time frame: Months 12, 24, and 34
Duration of Response Using the Competing Risk Approach - Cumulative Percentage of Participants With Progression, Relapse or Death as a Result of FL at 12, 24, and 34 Months
DOR was defined for all participants who achieved a response (CR, CRu, and PR) at Month 3 or later, after the completion of induction phase and was measured from the date of randomization until the date of progression, relapse, or death as a result of FL. Participants without relapse, progression, or death for causes other than FL were censored at their last assessment date. Analyses on this endpoint were performed with two different approaches. For the competing risk approach, deaths for causes other than FL were considered as competing events. DOR was estimated with the cumulative incidence of progression, relapse, or death as a result of FL.
Time frame: Months 12, 24, and 34
| Milestone | Induction Phase-Immunochemotherapy Rituximab-FND (R-FND) | Rituximab Induction, Rituximab Maintenance | Rituximab Induction, Observation Maintenance |
|---|---|---|---|
| Started | 234 | 0 | 0 |
| Completed | 202 | 0 | 0 |
| Not completed | 32 | 0 | 0 |
| Withdrew: Disease progression | 14 | 0 | 0 |
| Withdrew: Adverse event | 9 | 0 | 0 |
| Withdrew: Death | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 2 | 0 | 0 |
| Withdrew: Physician decision | 1 | 0 | 0 |
| Withdrew: Stable disease | 2 | 0 | 0 |
| Withdrew: Secondary neoplasia | 1 | 0 | 0 |
| Withdrew: Protocol violation | 1 | 0 | 0 |
| Milestone | Induction Phase-Immunochemotherapy Rituximab-FND (R-FND) | Rituximab Induction, Rituximab Maintenance | Rituximab Induction, Observation Maintenance |
|---|---|---|---|
| Started | 0 | 101 | 101 |
| Completed | 0 | 66 | 60 |
| Not completed | 0 | 35 | 41 |
| Withdrew: Disease progression | 0 | 23 | 29 |
| Withdrew: Adverse event | 0 | 3 | 1 |
| Withdrew: Death | 0 | 2 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 | 4 |
| Withdrew: Relapse | 0 | 5 | 5 |
| Withdrew: Physician decision | 0 | 0 | 1 |
PFS from randomization was measured from the date of randomization to the date of documented disease progression, relapse, or death from any cause. PFS function was estimated using Kaplan-Meier product-limit method. Responding participants and participants who were lost to follow up were censored at their last assessment date.
| percentage of participants | Rituximab Induction, Rituximab Maintenance | Rituximab Induction, Observation Maintenance |
|---|---|---|
| Percentage of Participants With Disease Progression or Death | 29.7 | 34.7 |
PFS from enrollment was measured from the date of enrollment to the date of disease progression, relapse, or death from any cause. Responding participants and participants who were lost to follow-up were censored at their last assessment date. Estimates of PFS function were made with the Kaplan-Meier product-limit method.
| percentage of participants | Rituximab Induction |
|---|---|
| 12 months | 90.1 (85.5 to 93.3) |
| 24 months | 77.8 (71.8 to 82.6) |
| 36 months | 65.7 (59.2 to 71.5) |
DFS was defined for all participants who achieved a complete response (CR) or unconfirmed CR (CRu) at Month 3 or later, after the completion of induction phase and was measured from the time of randomization to the date of relapse or death as a result of lymphoma or acute toxicity of treatment. Participants without relapse were censored at their last assessment date. Estimates of DFS were made using Kaplan-Meier product-limit method.
| percentage of participants | Rituximab Induction, Rituximab Maintenance | Rituximab Induction, Observation Maintenance |
|---|---|---|
| 12 months | 93.0 (85.8 to 96.6) | 82.5 (73.4 to 88.8) |
| 24 months | 82.7 (73.7 to 88.9) | 68.9 (58.7 to 77.2) |
| 36 months | 69.2 (57.9 to 78.1) | 62.3 (51.2 to 71.5) |
OS from randomization was defined as the date of randomization to the date of death from any cause. Participants still alive at the time of the final analysis were censored at the date of the last contact. Estimates of the OS function were made by the Kaplan-Meier product-limit method.
| percentage of participants | Rituximab Induction, Rituximab Maintenance | Rituximab Induction, Observation Maintenance |
|---|---|---|
| 12 months | 97.0 (91.0 to 99.0) | 100 (NA to NA) |
| 24 months | 96.0 (89.7 to 98.5) | 96.9 (90.6 to 99.0) |
| 34 months | 96.0 (89.7 to 98.5) | 95.8 (89.2 to 98.4) |
OS from randomization was defined as the date of randomization to the date of death from any cause. Participants still alive at the time of the final analysis were censored at the date of the last contact. Estimates of the OS function were made by the Kaplan-Meier product-limit method.
| percentage of participants | Rituximab Induction, Rituximab Maintenance | Rituximab Induction, Observation Maintenance |
|---|---|---|
| Overall Survival (OS) From Randomization - Percentage of Participants With Death | 5.0 | 4.0 |
OS from enrollment was defined as the date of enrollment to the date of death from any cause. Participants still alive at the time of the final analysis were censored at the date of the last contact. Estimates of the OS function were made by the Kaplan-Meier product-limit method.
| percentage of participants | Rituximab Induction, Rituximab Maintenance |
|---|---|
| 12 months | 94.9 (91.1 to 97.0) |
| 24 months | 92.7 (88.4 to 95.4) |
| 36 months | 89.5 (84.8 to 92.9) |
PFS from randomization was measured from the date of randomization to the date of documented disease progression, relapse, or death from any cause. Responding participants and participants who were lost to follow-up were censored at their last assessment date. PFS was estimated using Kaplan-Meier methods.
| percentage of participants | Rituximab Induction, Rituximab Maintenance | Rituximab Induction, Observation Maintenance |
|---|---|---|
| 12 months | 92.0 (84.7 to 95.9) | 82.5 (73.4 to 88.8) |
| 24 months | 81.0 (71.8 to 87.4) | 68.9 (58.7 to 77.2) |
| 34 months | 70.4 (60.2 to 78.4) | 62.3 (51.2 to 71.5) |
Participants without a response assessment (due to any reasons) were considered as non-responders.
| percentage of participants | Rituximab Induction, Rituximab Maintenance | Rituximab Induction, Observation Maintenance |
|---|---|---|
| Complete remission (CR/CRu) | 79.2 | 79.2 |
| Partial remission | 19.8 | 19.8 |
| Stable disease | 1.0 | 0.0 |
| Progression disease | 0.0 | 0.0 |
| Missing | 0.0 | 1.0 |
Molecular responders were defined as the proportion of CR/CRu participants with a positive bcl-2/IgH (non-Hodgkin's Lymphoma \[NHL\] marker) at baseline, whose laboratory values were undetectable after treatment.
| percentage of participants | Rituximab Induction, Rituximab Maintenance |
|---|---|
| Month 5 | 36.4 |
| Month 8 | 58.5 |
Duration of response (DOR) was defined for all participants who achieved a response (CR, CRu, and PR) at Month 3 or later, after the completion of induction phase and was measured from the date of randomization until the date of progression, relapse, or death as a result of follicular lymphoma (FL). Participants without relapse, progression, or death for causes other than FL were censored at their last assessment date. Analyses on this endpoint were performed with two different approaches. For the traditional approach, duration of response was estimated as the proportion of participants alive without progression or relapse of disease with the Kaplan-Meier method.
| percentage of participants | Rituximab Induction, Rituximab Maintenance | Rituximab Induction, Observation Maintenance |
|---|---|---|
| 12 Months | 93.9 (86.9 to 97.2) | 82.3 (73.1 to 88.6) |
| 24 Months | 83.6 (74.6 to 89.6) | 68.6 (58.3 to 76.9) |
| 34 Months | 69.9 (58.5 to 78.7) | 61.9 (50.9 to 71.2) |
DOR was defined for all participants who achieved a response (CR, CRu, and PR) at Month 3 or later, after the completion of induction phase and was measured from the date of randomization until the date of progression, relapse, or death as a result of FL. Participants without relapse, progression, or death for causes other than FL were censored at their last assessment date. Analyses on this endpoint were performed with two different approaches. For the competing risk approach, deaths for causes other than FL were considered as competing events. DOR was estimated with the cumulative incidence of progression, relapse, or death as a result of FL.
| percentage of participants | Rituximab Induction, Rituximab Maintenance | Rituximab Induction, Observation Maintenance |
|---|---|---|
| 12 Months | 6.1 (1.3 to 10.8) | 17.7 (10.0 to 25.3) |
| 24 Months | 16.2 (8.9 to 23.5) | 31.4 (22.0 to 40.8) |
| 34 Months | 29.5 (19.5 to 39.6) | 38.0 (27.8 to 48.3) |
Collected over Adverse events (AEs) were reported up to Month 15.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rituximab Induction (Induction Phase Only) | — | 19/233 (8.2%) | 230/233 (98.7%) |
| Rituximab Induction, Rituximab Maintenance (Follow-up Phase) | — | 19/101 (18.8%) | 73/101 (72.3%) |
| Rituximab Induction, Observation Maintenance (Follow-up Phase) | — | 17/101 (16.8%) | 55/101 (54.5%) |
| Event | Rituximab Induction (Induction Phase Only) | Rituximab Induction, Rituximab Maintenance (Follow-up Phase) | Rituximab Induction, Observation Maintenance (Follow-up Phase) |
|---|---|---|---|
| CholelithiasisGastrointestinal disorders | 0/233 | 0/101 | 3/101 |
| Hepatitis BInfections and infestations | 1/233 | 1/101 | 2/101 |
| Myocardial infarctionCardiac disorders | 0/233 | 2/101 | 0/101 |
| PneumoniaInfections and infestations | 0/233 | 2/101 | 2/101 |
| Angina pectorisCardiac disorders | 0/233 | 0/101 | 2/101 |
| PyrexiaImmune system disorders | 2/233 | 0/101 | 1/101 |
| Abdominal painGastrointestinal disorders | 1/233 | 1/101 | 0/101 |
| NeutropeniaBlood and lymphatic system disorders | 0/233 | 1/101 | 0/101 |
| Cardiac ablationCardiac disorders | 0/233 | 1/101 | 0/101 |
| Wolff-Parkinson-White syndromeCardiac disorders | 0/233 | 1/101 | 0/101 |
| Event | Rituximab Induction (Induction Phase Only) | Rituximab Induction, Rituximab Maintenance (Follow-up Phase) | Rituximab Induction, Observation Maintenance (Follow-up Phase) |
|---|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 225/233 | 16/101 | 2/101 |
| ThrombocytopeniaBlood and lymphatic system disorders | 120/233 | 2/101 | 1/101 |
| AnaemiaBlood and lymphatic system disorders | 103/233 | 1/101 | 1/101 |
| Asthenia/fatigueGeneral disorders | 57/233 | 0/101 | 0/101 |
| PyrexiaGeneral disorders | 44/233 | 8/101 | 3/101 |
| NauseaGastrointestinal disorders | 43/233 | 0/101 | 0/101 |
| PainGeneral disorders | 31/233 | 0/101 | 13/101 |
| CoughRespiratory, thoracic and mediastinal disorders | 17/233 | 13/101 | 10/101 |
| ConstipationGastrointestinal disorders | 24/233 | 1/101 | 1/101 |
| DiarrhoeaGastrointestinal disorders | 23/233 | 2/101 | 1/101 |
Intention-to-Treat (ITT) population: all participants who were randomized to the maintenance or observation arm. IP population: all enrolled participants who started the induction phase (Months 1-8 of the study)
| Age, Continuous(years) | Rituximab Induction, Rituximab Maintenance | Rituximab Induction, Observation Maintenance | Total |
|---|---|---|---|
| Median | 66 (64 to 70) | 65 (62 to 69) | 66 (63 to 69) |
| Sex: Female, Male(Participants) | Rituximab Induction, Rituximab Maintenance | Rituximab Induction, Observation Maintenance | Total |
|---|---|---|---|
| Female | 64 | 56 | 120 |
| Male | 37 | 45 | 82 |
Ran from Jan 2004 to primary completion in Jul 2011, 90 months.
Results were first posted in Dec 2014, 3 years 4 months after primary completion.
Of 41 industry-sponsored phase 3 interventional studies under Lymphoma, Non-Hodgkin, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 43 and three quarters within 84. This study's 90 months is above that.
Counting every sponsor, half of 58 studies reached it within 68 months; a quarter within 43 and three quarters within 86.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rituximab